TwoStep Raises $62.5 Million as TS-104 Clears IND
TwoStep Therapeutics closed an oversubscribed $62.5 million Series A and received FDA clearance to begin first-in-human testing of TS-104, a peptide-drug conjugate designed to bind five tumor-associated integrins. The financing funds Phase I development,…
